Business Wire

NEXTEK-LIMITED

20.10.2021 11:32:06 CEST | Business Wire | Press release

Share
Award-winning British Recycling Project, NEXTLOOPP, Hits Bullseye in Plastics Recycling Ahead of COP26

NEXTLOOPP, the groundbreaking project by Nextek Limited, that recently won the overall award for ‘Best Sustainable Packaging Innovation’ at Packaging Europe’s Sustainability Awards - https://packagingeurope.com/sustainability-awards-2021-winners-revealed/ has revealed the results of its highly successful tracer-based sorting trials held at TOMRA (Germany) in September 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005464/en/

The trials, to specifically sort food-grade plastic packaging waste, achieved a resounding 99.9% sorting purity at maximum production speed.

This demonstrates that Nextek’s unique technology efficiently differentiates food packaging from non-food packaging to meet the standards required by the Food Standards Authorities in the UK and EU. Being able to identify and sort any number of pack variants from bleach bottles to milk bottles in any plastic type is a world-first that will transform the way we recycle the prolific volume of single-use post-consumer food packaging waste back into circular applications.

This announcement marks 12 months of NEXTLOOPP’s programme to close the loop on food-grade Polypropylene (FGPP), which is the biggest plastic fraction in the FMCG sector. In the UK alone, 210,000 tonnes of FGPP packaging is used in pots, tubs, trays and films each year, and this cutting-edge innovation creates the opportunity to recycle Polypropylene (PP) back into food packaging.

This also heralds a new era in the plastics packaging recycling industry and the validation of NEXTLOOPP’s PolyPRISMTM ‘plug-and-play’ marker system, as used on TOMRA’s sorting equipment for commercial purposes.

Sorting plastic waste into polymer types is the first of three vital steps needed to close the loop on PP and create a global low carbon economy. The next step requires splitting the plastic packaging into food and non-food fractions. The final step involves NEXTLOOPP’s patented decontamination process, PPristineTM , which unlocks the markets to food packaging. Recycling 63,000 tonnes of PP per annum would save a minimum estimated 105,600 tonnes in CO2 emissions in the UK each year.

“During recent trials held at our TOMRA Test Centre we achieved very promising results on all Polypropylene 3D samples in all test runs with state-of-the-art NIR/VIS technology. We exceeded the required 95% purity for food-grade in each test run. The next important milestones will be a field demonstration as well as demonstrating chemical compliance with food-grade regulation” said Ralph Uepping, Technical Director at TOMRA.

Professor Edward Kosior, founder of Nextek, believes the NEXTLOOPP project is the catalyst to transform current FGrPP recycling and become the next food-grade recycling success story. PET was first and now it’s the turn of PP.

About Nextek Ltd

Nextek is a global sustainability consultancy that provides strategic advice to regional and multi-national organisations and recycling companies. Launched in 2004, Nextek researches and develops innovative strategies and processes within the recycling ecosystem – from designing recycling plants to developing ground-breaking projects for governments and major organisations. Nextek launched NEXTLOOPP, a two-year 37-strong project, to close the loop on food-grade recycled Polypropylene (rPP). This project incorporates unique technological breakthroughs that include innovative sorting and cutting-edge decontamination technologies.

https://www.nextek.org/

https://www.nextloopp.com

About Tomra

TOMRA is a Norwegian multinational corporation that manufactures collection and sorting products, such as reverse vending machines for the food, recycling and mining industries. TOMRA is the market leader in its industry with over 100,000 installations in 80+ markets worldwide. Its Recycling Division has pioneered the automation of waste sorting.

https://www.tomra.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye